



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

OCT 20 2009

David B. Quick
ICE MILLER LLP
One American Square
Suite 2900
Indianapolis, IN 46282-0200

In Re: Patent Term Extension
Application for
U.S. Patent No. 4,919,140

Dear Mr. Quick :

An interim extension under 35 U.S.C. § 156(d)(5) is enclosed extending the term of U.S. Patent No. 4,919,140 for a period of 1 year. A copy of the Federal Register notice published in accordance with 35 U.S.C. 156(d)(5)(B) on October 16, 2009 at 74 Fed. Reg. 53217 is enclosed herewith. While a courtesy copy of this letter and the interim extension is being forwarded to the Food and Drug Administration (FDA), you should directly correspond with the FDA regarding any required changes to patent expiration dates.

Inquiries regarding this communication should be directed to the undersigned by telephone at (571) 272-7755, or by e-mail to mary.till@uspto.gov.

Mary C. Till
Legal Advisor
Office of Patent Legal Administration
Office of the Deputy Commissioner
for Patent Examination Policy

cc: Office of Regulatory Policy
Food and Drug Administration
10903 New Hampshire Ave., Bldg. 51, Rm. 6222
Silver Spring, MD 20993-0002

RE: Andara™ OFS™ System
FDA Docket No.:

Attention: Beverly Friedman

UNITED STATES PATENT AND TRADEMARK OFFICE


In re Purdue Research Foundation :
Request for Patent Term Extension : **ORDER GRANTING**
U.S. Patent No. 4,919,140 : **INTERIM EXTENSION**

On September 11, 2009, the patent owner, Purdue Research Foundation, timely filed a second application under 35 U.S.C. § 156(d)(5) for an interim extension of the term of U.S. Patent No. 4,919,140. The patent claims the medical device known as Andara™ OFS™ System and a method of using the Andara™ OFS™ System. The application indicates that a Humanitarian Device Exemption, HDE 070002, for the medical device Andara™ OFS™ System has been filed and is currently undergoing regulatory review before the Food and Drug Administration for permission to market or use the product commercially.

Review of the application indicates that except for permission to market or use the product commercially, the subject patent would be eligible for an extension of the patent term under 35 U.S.C. § 156, and that the patent should be extended for an additional one year as required by 35 U.S.C. § 156(d)(5)(B). Because it is apparent that the regulatory review period will continue beyond the extended expiration date of the patent (October 14, 2009), interim extension of the patent term under 35 U.S.C. § 156(d)(5) is appropriate.

A second interim extension under 35 U.S.C. § 156(d)(5) of the term of U.S. Patent No. 4,919,140 is granted for a period of one year from the expiration date of the patent, i.e., until October 14, 2010.

10/09/09
Date



David J. Kappos
Under Secretary of Commerce for Intellectual Property and
Director of the United States Patent and Trademark Office